Ehlers-Danlos Type 3 (hEDS): Symptoms and Testing

Medically reviewed by Brandon Colby, MD, last reviewed Oct 16, 2026

Short answer: No single genetic test can confirm hypermobile Ehlers-Danlos syndrome (hEDS), because no specific gene has been identified. Doctors diagnose it from symptoms, history and clinical criteria. Genetic testing is used mainly to look for other conditions that can look similar and to understand family risk.

Update coming in December 2026: The criteria used to diagnose Ehlers-Danlos syndrome (EDS) and hypermobility spectrum disorders (HSD) are being updated for the first time since 2017. If you already have a diagnosis, you do not need to be reevaluated just because the classification is changing. Read our EDS diagnostic criteria update to see what changes for you.

Ehlers-Danlos Syndrome, Type 3, also known as hypermobility Ehlers-Danlos syndrome (hEDS), is a complex connective tissue disorder characterized by joint hypermobility, skin elasticity, and a variety of other symptoms. As the understanding of genetic influences on health advances, genetic testing is becoming an increasingly valuable tool in diagnosing and managing this enigmatic condition. This article delves into the potential benefits and uses of genetic testing for individuals suspected of having hEDS.

Understanding Ehlers-Danlos Syndrome, Type 3

Ehlers-Danlos Syndrome (EDS) comprises a group of connective tissue disorders, each with unique genetic causes and clinical manifestations. Type 3, or hypermobility EDS, is the most common form and presents primarily with joint hypermobility. Other symptoms may include chronic pain, fatigue, and skin that bruises easily. Despite its prevalence, hEDS is notoriously difficult to diagnose due to its overlapping symptoms with other hypermobility disorders and the lack of specific genetic markers.

The Promise of Genetic Testing in hEDS

Identifying Genetic Variants

Genetic testing can play a crucial role in identifying potential genetic variants associated with hEDS. While a definitive genetic marker for hEDS has yet to be identified, ongoing research aims to uncover specific genetic mutations that may contribute to the condition. By analyzing an individual's genetic makeup, healthcare providers can better understand the potential hereditary components of hEDS, leading to more accurate diagnoses and personalized treatment plans.

Informing Clinical Management

For individuals with hEDS, genetic testing can provide valuable insights into the nature and extent of their condition. Understanding the genetic underpinnings of hEDS can help clinicians tailor management strategies to address specific symptoms and complications. For example, if genetic testing reveals a predisposition to certain cardiovascular issues, a more proactive approach to monitoring and managing heart health can be adopted. This personalized approach can improve quality of life and reduce the risk of complications.

Facilitating Family Planning

Genetic testing is also beneficial for family planning purposes. Individuals with hEDS who are considering having children may wish to understand the likelihood of passing the condition onto their offspring. Genetic counseling, informed by testing results, can provide prospective parents with the information needed to make informed decisions about family planning. This knowledge empowers families to anticipate potential challenges and prepare accordingly.

Advancing Research and Treatment Options

As more individuals undergo genetic testing, the resulting data can significantly contribute to research efforts aimed at understanding hEDS. Large-scale genetic studies can identify patterns and correlations that may lead to the discovery of new genetic markers and potential treatment targets. This collective knowledge can drive the development of novel therapies and interventions, ultimately improving outcomes for individuals with hEDS.

Challenges and Considerations

While the potential benefits of genetic testing for hEDS are substantial, there are also challenges and considerations to keep in mind. The lack of a specific genetic marker for hEDS means that testing may not always yield definitive answers. Additionally, genetic testing can be costly and may not be covered by insurance. Ethical considerations, such as privacy concerns and the psychological impact of genetic information, must also be addressed.

Despite these challenges, the integration of genetic testing into the diagnostic and management processes for hEDS holds promise. By continuing to explore the genetic landscape of hEDS, researchers and clinicians can work towards more accurate diagnoses, personalized treatments, and improved quality of life for those affected by this complex condition.

What Is the December 2026 EDS Diagnostic Criteria Update?

The Ehlers-Danlos Society is expected to publish an updated classification framework for the Ehlers-Danlos syndromes and hypermobility spectrum disorders in December 2026, the first major update since 2017. If you already have a diagnosis, you do not need to be reevaluated solely because the classification is changing. The update is also expected to revisit how hypermobile EDS and hypermobility spectrum disorders are defined. Current public findings have not identified a reliable molecular test for either, so they remain clinical diagnoses. See how Sequencing is preparing in our guide to the EDS classification update.

Research on Hypermobile EDS and Dysautonomia

Sequencing and the Norris Lab at the Medical University of South Carolina have opened a research study on hypermobile EDS (hEDS) and dysautonomia. If you already have whole genome sequencing with Sequencing, you can choose whether to take part. Participation is voluntary, data is de-identified, and individual results are not returned. Read why we are launching our patient driven genetic study for hypermobile Ehlers-Danlos syndrome and dysautonomia.

Get Tested With Whole Genome Sequencing

Our whole genome sequencing screens all genes known to be associated with Ehlers-Danlos syndromes. This includes the established genes linked to classical and vascular forms, as well as emerging research markers such as KLK15, which has a preliminary research link to hEDS. Hypermobile EDS remains a clinical diagnosis, so bring your results to a clinician who knows connective tissue disorders.

Shop All Whole Genome Sequencing Kit Bundles

Frequently Asked Questions About Hypermobile Ehlers-Danlos Syndrome

What is hypermobile Ehlers-Danlos syndrome (hEDS)?

Hypermobile Ehlers-Danlos syndrome, also called Ehlers-Danlos syndrome type 3, is a connective tissue disorder. It mainly causes joint hypermobility and can also cause chronic pain, fatigue, skin that stretches, and easy bruising. It is the most common type of Ehlers-Danlos syndrome.

Is there a genetic test that confirms hEDS?

No. A specific gene for hEDS has not been identified, so a genetic test cannot confirm or rule it out. Doctors diagnose hEDS from a person's symptoms, medical history and clinical criteria.

Why is hEDS hard to diagnose?

Its symptoms overlap with other hypermobility disorders, and there is no specific genetic marker to test for.

How can genetic testing help if it cannot confirm hEDS?

Testing can look for variants linked to other connective tissue conditions that can look similar, which can change how a person is monitored and treated. It can also help families and doctors understand hereditary patterns, and results add to research. A doctor or genetic counselor can explain what a result does and does not mean.

Can hEDS be passed on to my children?

hEDS can run in families. Because no gene has been identified, a genetic test cannot tell you the chance of passing it on. A genetic counselor can review your family history with you and talk through family planning.

Does Sequencing test for hEDS?

No test, including ours, can confirm hEDS. Sequencing's whole genome sequencing reads 100% of your DNA, so your results can be reviewed for genes linked to other Ehlers-Danlos types and related connective tissue conditions. Bring your results to a doctor who knows connective tissue disorders.

What should I do if I think I have hEDS?

Talk with a doctor who is familiar with connective tissue disorders. Your doctor will review your symptoms, your medical history and your family history, and will examine your joints.

References

Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017. doi:10.1002/ajmg.c.31552

This article is for education and is not a substitute for professional medical advice, diagnosis, or treatment. Talk to a qualified healthcare provider about your own health.